post-bg-448
calendary October 14, 2024

The United States the first in several decades drug for the treatment of schizophrenia has been approved

According to the World Health Organization, schizophrenia is one of the 15 main causes of disability in the world. In specialized clinics, 50 % are patients with this diagnosis. Traditional therapies for schizophrenia include drugs that act on dopamine receptors, while the new drug involves acting on cholinergic receptors in the brain.

On September 26, 2024, the news about the approval of the drug Cobenfy (xanomeline and trospium chloride) manufactured by Bristol Myers Squibb (BMS) appeared on the website of the US Food and Drug Administration (FDA).

The drug Cobenfy is the first antipsychotic in the last few decades, the action of which is based on a fundamentally new approach – the effect on the cholinergic receptors of the brain.

The drug has shown its effectiveness in two clinical trials identical in design. In both trials, patients taking the drug had a decrease in the severity of schizophrenia symptoms in the fifth week compared with the placebo group.

BMS plans to bring Cobenfy to the market at the end of October 2024 at a price of $1,850 per month and $22,500 per year.

Schizophrenia is a mental disorder characterized by a combination of productive (hallucinatory-delusional, catatonic-hebephrenic, affective, etc.) and negative (apathy, abulia, alogia, emotional and social isolation, etc.) symptoms, behavioral and cognitive disorders (memory, attention, thinking, etc.) and leading to adverse social and economic consequences.

Currently, the stress-diathesis model of the origin of schizophrenia is generally accepted, which reflects the idea of the importance of not only hereditary, but also environmental, including social factors in the development of the disease.

Thus, the risk of schizophrenia increases in cases when a person grew up in an urban environment, compared with living in rural areas, is a migrant and uses cannabinoids. Risk factors, in addition, include obstetric and gynecological complications (premature birth, fetal hypoxia), infectious diseases and maternal malnutrition in the first and early second trimester of pregnancy, infectious diseases during pregnancy - influenza, rubella, toxoplasmosis, herpes, as well as early childhood psychological trauma. In recent years, special attention has been paid to the microbiota in relation to the development of schizophrenia.

References:
  1. https://www.fda.gov/news-events/press-announcements/fda-approves-drug-new-mechanism-action-treatment-schizophrenia
  2. https://www.who.int/news-room/fact-sheets/detail/schizophrenia
  3. https://cr.minzdrav.gov.ru/schema/451_2
  4. https://pharmvestnik.ru/content/news/FDA-odobrilo-pervyi-za-neskolko-desyatiletii-preparat-ot-shizofrenii.html

More related posts

new-img-1

Control

Fine for spa resort in Yessentuki

Roszdravnadzor has imposed a fine of 130 thousand rubles on a spa resort in Yessentuki for improper storage of medical products…

03.03.2016
READ ARTICLE
new-img-2

Roszdravnadzor

Roszdravnadzor – patients’ rights

In 2015, Roszdravnadzor restored the rights of more than 460 thousand citizens to effective, accessible, and safe medical…

03.03.2016
READ ARTICLE
new-img-3

Regulation

The certification scheme for medical products hasn’t changed recently

Roszdravnadzor informs that the certification scheme for products in the Russian Federation is determined by Decree of the…

03.04.2016
READ ARTICLE
new-img-4

Control

Fines – Rostov region

In one and a half months of 2016, the Local Agency of Roszdravnadzor in Rostov Region imposed fines of the total amount of…

03.10.2016
READ ARTICLE
new-img-5

Control

Unregistered medical products

Two citizens were fined for selling unregistered medicinal products on the Internet in the Republic of Bashkortostan.

03.10.2016
READ ARTICLE
new-img-6

Control

Unscheduled inspection by roszdravnadzor

Roszdravnadzor started an unscheduled inspection of the Federal State-Funded Institution of Sverdlovsk Region Kirovgrad Central…

03.14.2016
READ ARTICLE
new-img-7

Medical Devices

International medical device regulators forum (IMDRF)

The delegation of the Federal Service for Surveillance in Healthcare headed by Mikhail Murashko, Head of Roszdravnadzor,…

03.17.2016
READ ARTICLE
new-img-8

Pharmaceuticals

Roszdravnadzor has suspended a series of the preparation “Paratsetomol-UBF”

Roszdravnadzor has suspended a series of the preparation “Paratsetomol-UBF” in which pills the metal wire was found.

05.18.2016
READ ARTICLE
new-img-9

Roszdravnadzor

Medical equipment stands idle in the Pskov region

Roszdravnadzor (RZN) statement: the expensive medical equipment for the total amount of 342 million rubles stands idle in…

05.19.2016
READ ARTICLE
new-img-10

Control

Hospital control Jewish autonomous region

Roszdravnadzor has audited the activity of the Regional Budgetary Public Health Facility “Central district hospital of Lenin”…

05.20.2016
READ ARTICLE